Literature DB >> 9837851

Modulating the immune response to genetic immunization.

A D Cohen1, J D Boyer, D B Weiner.   

Abstract

Genetic immunization, also known as DNA or polynucleotide immunization, is a novel strategy for vaccine development in which plasmid DNA encoding either individual or a collection of antigens is directly administered to a host. Such immunization leads to host expression of the delivered foreign gene, resulting in the induction of a specific immune response against the in vivo produced antigen. DNA immunization has been shown to induce protective immune responses in several infectious disease and cancer experimental model systems. Furthermore, DNA vaccines have recently entered the clinic for analysis as both prophylactic and therapeutic agents. Although the mechanisms of immunity to DNA have not yet been fully elucidated, it has become apparent that the immune response achieved by DNA vaccination is quite malleable, and can be manipulated by altering the conditions under which the vaccine is administered. Either through changing the method or location of immunization, altering the number of immunostimulatory sequences in the plasmid, altering the immunization regimen, or coadministering genes for cytokines or costimulatory molecules, one can modulate both the magnitude and orientation of the subsequent immune response. Through maximization of this feature of DNA immunization, we will likely be able to design vaccines and immunotherapeutic agents that are tailored to the correlates of protection for a particular disease, resulting in a new generation of more focused and effective immune stimulating agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837851

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  20 in total

Review 1.  Pre-priming: a novel approach to DNA-based vaccination and immunomodulation.

Authors:  H Kobayashi; A A Horner; E Martin-Orozco; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug.

Authors:  Jehad Charo; Maria Sundbäck; Ken Wasserman; Anne-Marie T Ciupitu; Babak Mirzai; Ruurd van der Zee; Rolf Kiessling
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

4.  Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors.

Authors:  Shin Sasaki; Rama Rao Amara; Wen-Shuz Yeow; Paula M Pitha; Harriet L Robinson
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 5.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

6.  Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.

Authors:  Osmarie Martínez; Ariana Bravo Cruz; Saritza Santos; Maite Ramírez; Eric Miranda; Joanna Shisler; Miguel Otero
Journal:  Vaccine       Date:  2017-06-16       Impact factor: 3.641

7.  CpG motif acts as a 'danger signal' and provides a T helper type 1-biased microenvironment for DNA vaccination.

Authors:  Ling Liu; Xiaohui Zhou; Hua Liu; Li Xiang; Zhenghong Yuan
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

10.  Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen.

Authors:  Haim Grosfeld; Sara Cohen; Tamar Bino; Yehuda Flashner; Raphael Ber; Emanuelle Mamroud; Chanoch Kronman; Avigdor Shafferman; Baruch Velan
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.